Method for reducing listeria monocytogenes infection by inhibiting host CypD protein synthesis

By constructing CypD-deficient cells using CRISPR-Cas9 gene editing technology and employing PPIF gene expression inhibitors or CypD protein inhibitors, the problem of Listeria monocytogenes enhancing its infectivity by regulating host cell mitochondria was solved, achieving a significant reduction in its proliferation.

CN121338043APending Publication Date: 2026-01-16ZHEJIANG FORESTRY UNIVERSITY
0 Cites 0 Cited by

Patent Information

Application Number
CN202511358116.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-09-22
Publication Date
2026-01-16

AI Technical Summary

Technical Problem

Listeria monocytogenes enhances its adhesion, invasion, and spread by regulating the mitochondrial structure and function of host cells. Current technologies have not yet effectively addressed the role of CypD in Listeria monocytogenes infection.

Method used

HeLa and THP-1 cells lacking CypD were constructed using CRISPR-Cas9 gene editing technology. Listeria monocytogenes infection was reduced using PPIF gene expression inhibitors or CypD protein inhibitors, including the preparation of drugs using PPIF gene expression inhibitors or CypD protein inhibitors, vectors that inactivate or reduce PPIF gene expression, or recombinant microorganisms containing such vectors.

Benefits of technology

It significantly reduces the intracellular proliferation capacity of Listeria monocytogenes without affecting cell growth activity, providing a basis for the clinical prevention and treatment of Listeria monocytogenes infection.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of biology, in particular to a method for reducing listeria monocytogenes infection by inhibiting host CypD protein synthesis. Specifically, the invention finds that the proliferation of the listeria monocytogenes in cells can be obviously reduced and the growth activity of the cells is not influenced by inactivating or inhibiting the expression of the CypD protein (the coding gene is PPIF), and a basis is provided for preventing and treating the infection of the listeria monocytogenes by clinically utilizing a PPIF gene expression inhibitor or a CypD protein synthesis inhibitor. On the basis, on one hand, the invention provides application of a PPIF gene expression inhibitor or a CypD protein synthesis inhibitor in reduction of listeria monocytogenes infection. On the other hand, the invention provides an application of a vector for inactivating the PPIF gene or reducing expression of the PPIF gene or an engineered cell or a recombinant microorganism containing the vector in reduction of Listeria monocytogenes infection.
Need to check novelty before this filing date? Find Prior Art